A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression
Phase: PHASE2 | Sponsor: Beersheva Mental Health Center | Compound: Psilocybin
- Status
- recruiting
- Institution
- Beersheva Mental Health Center
- Start date
- 2025-12-01
- End date
- 2028-06-01
- Registry ID
- NCT07183748
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.